<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58689">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895634</url>
  </required_header>
  <id_info>
    <org_study_id>Rev-01</org_study_id>
    <nct_id>NCT01895634</nct_id>
  </id_info>
  <brief_title>Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)</brief_title>
  <official_title>Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson K.K. Medical Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson K.K. Medical Company</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to document that the thrombectomy catheter (Rev-01) is
      effective and safe when used for revascularization in subjects with acute ischemic stroke
      within 8 hours of symptom onset who are ineligible for treatment with IV t-PA, or in whom
      treatment with IV t-PA has been ineffective.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients who have recanalization</measure>
    <time_frame>immediately post device procedural angiograms, after the device is removed and before final closure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Following neurological outcomes    - mRS score    - NIHSS score    - BI score</measure>
    <time_frame>90-day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with  ICH (symptomatic and asymptomatic)</measure>
    <time_frame>24-hour post procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>90 days post-procedure</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Device: Rev-01</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rev-01</intervention_name>
    <description>Treatment arm patients have used Rev-01 at least once</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Onset of symptom is &lt;= 8 hours prior to treatment with Rev-01

          -  Treatment with IV t-PA is ineligible or ineffective

          -  Occluded (presenting TICI score of 0 or 1) M1 or M2 of MCA, basilar or vertebral
             artery, or intracranial segment of ICA, confirmed by angiography that it is
             accessible to the Rev-01

          -  NIHSS score is 8-30

          -  Prior to new focal disabling neurologic deficit, mRS score was 0-2

        Key Exclusion Criteria:

          -  Acute intracranial hemorrhage

          -  Mass effect or intracranial tumor

          -  Extended early ischemic changes evidenced by CT or MRI

          -  Administration of heparin within 48 hours preceding the onset of stroke and have an
             elevated APTT or PTT above twice of the normal range for the laboratory at
             presentation

          -  Known bleeding diathesis of current use of oral anticoagulants (e.g., warfarin
             sodium) with International Normalized Ration (INR) &gt; 3

          -  Platelet count &lt; 30,000/mm3

          -  Glucose &lt; 50 mg/dL

          -  Severe sustained hypertension (SBP &gt; 185mmHG or DBP &gt; 110mmHG) refractory to
             pharmacological management

          -  Life expectancy of less than 90 days

          -  Pregnancy or females who are lactating

          -  Current participation in an investigational drug or device study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nobuyuki Sakai, M.D., D.M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kobe City Medical Center General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kumiko Yagi</last_name>
    <phone>+81-3-4411-6789</phone>
    <email>kyagi1@its.jnj.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kobe City Medical Center General Hospital</name>
      <address>
        <city>Kobe-city</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 25, 2014</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemia</keyword>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Thrombectomy</keyword>
  <keyword>Brain clot</keyword>
  <keyword>Cerebrovascular disease</keyword>
  <keyword>Recanalization</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Clot Retriever</keyword>
  <keyword>Neurovascular Intervention</keyword>
  <keyword>Interventional Neuroradiology</keyword>
  <keyword>neurovascular clinical trial</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
